What the FDA labels say about taking them together
Rifapentine and sofosbuvir
Sofosbuvir's FDA label of December 26, 2024 names rifapentine in its drug interactions section; the rifapentine label PlainMeds reads does not name sofosbuvir. The sofosbuvir label: “Coadministration of SOVALDI with rifabutin or rifapentine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI. Coadministration is not recommended. …”
Check it at the source: the rifapentine FDA label on DailyMed (effective February 6, 2026, sanofi-aventis U.S. LLC); the sofosbuvir FDA label on DailyMed (effective December 26, 2024, Gilead Sciences, Inc.).
What does the rifapentine label say about sofosbuvir?
Rifapentine's label (effective February 6, 2026) does not name sofosbuvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Priftin), sanofi-aventis U.S. LLC, effective February 6, 2026 (SPL set 3a64fb70-b85e-43d9-8bcd-7e893f568ae1), via openFDA; the full label on DailyMed
What does the sofosbuvir label say about rifapentine?
Sofosbuvir label, drug interactionsConcomitant Drug Class/Drug Name: Antimycobacterials: Rifabutin rifampin rifapentine; Effect on Concentration ↓ = decrease.: ↓ sofosbuvir ↓ GS-331007; Clinical Comment: Coadministration of SOVALDI with rifabutin or rifapentine is expected to decrease the concentration of sofosbuvir, leading to reduced therapeutic effect of SOVALDI. Coadministration is not recommended. Coadministration of SOVALDI with rifampin, an intestinal P-gp inducer, is not recommended [see].
Source: FDA drug label (Sovaldi), Gilead Sciences, Inc., effective December 26, 2024 (SPL set 80beab2c-396e-4a37-a4dc-40fdb62859cf), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rifapentine | Sofosbuvir | |
|---|---|---|
| Labeled for | n/a | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $4.83 per tablet 150 mg tablet | n/a |
| Shortage now | Resolved | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once